WuXi AppTec, the Shanghai-based biotech giant, has sold its South Philly-based WuXi Advanced Therapies contract manufacturing unit to New York-based Altaris LLC, easing worries that federal limits ...

WuXi STA expects to hire about 500 people in the coming years to support Phase 1 of the manufacturing campus. A Chinese pharmaceutical company is moving forward with plans to build a massive $510 ...

Additionally, he described how WuXi AppTec plans this year to move forward with the construction of a pharmaceutical manufacturing campus in Delaware, set to come online in 2026 and eventually ...

WuXi AppTec Co. and WuXi Biologics Cayman Inc. said they see a brighter 2025 for the Chinese biotech and drug companies after the US Biosecure legislation that threatened to cut them out from ...

MSD has expanded its presence in Ireland with an agreement to buy a vaccine manufacturing facility from Chinese biotech WuXi Biologics for around €500 million (around $520 million). The plant in ...

It is well known that WuXi entities have become dangerously entwined with American biotech. BGI Group's genomic data collection and ties to the Chinese military have alarmed national security ...

Ranked among the top 1% of companies assessed in the pharmaceutical industry <li /> Recognized as a leader in Green CRDMO, driving innova ...

The U.S. tariffs on China include a broad 10% levy on imported goods. China’s response was more targeted, with 15% tariffs on ...

If passed, the bill would prohibit US federal funding for any company that outsources services to biotechnology companies in China. Drafts of the bill explicitly name WuXi Biologics and WuXi AppTec.

Shares of WuXi AppTec Co Ltd and WuXi Biologics (Cayman) tumbled on Friday as investor fears grew over a U.S. draft bill targeting Chinese biotech giants.